Onco Wiki / Maladie

Lymphome B-Cell hautement qualifié avec réarrangements MYC et BCL2 et/ou BCL6 (double-hit / triple-hitch)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-HGBL-DH
TypeMaladie
Alias
DH/THLLymphome à double-chocHGBLHGBL-DHLymphome B de haut grade, double-hit / triple-hitВисокозлоякісна B-клітинна лімфома з MYC + BCL2/BCL6 (double-hit / triple-hit)
Étatreviewed 2026-04-25 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-NCCN-BCELL-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9680/3
icd_10C83.3
who_classificationAggressive B-cell lymphomas — High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements per WHO 5th ed.

Capacités

Notes

Mandatory FISH break-apart for MYC + BCL2 + BCL6 on every newly- diagnosed DLBCL — without it, double-hit is missed. Distinct from Burkitt (Ki67 ~100%, BCL2−) by Ki67 typically 70-90% + BCL2+.

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Indication

Questionnaires

Signal d’alerte

Sources